Other analysts have also recently issued reports about the company. Citigroup upgraded Radius Health from a neutral rating to a buy rating and boosted their price objective for the company from $24.00 to $40.00 in a research report on Thursday, August 29th. Cowen restated a hold rating on shares of Radius Health in a research report on Thursday, August 8th. Morgan Stanley started coverage on Radius Health in a research report on Thursday, September 5th. They issued a buy rating and a $43.00 price objective for the company. Finally, BidaskClub upgraded Radius Health from a hold rating to a buy rating in a research report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $36.50.
Shares of Radius Health stock traded down $0.34 on Wednesday, reaching $25.75. The company’s stock had a trading volume of 409,845 shares, compared to its average volume of 661,982. The company has a market capitalization of $1.20 billion, a P/E ratio of -5.28 and a beta of 0.78. Radius Health has a 52-week low of $12.81 and a 52-week high of $29.97. The stock has a 50-day moving average price of $26.44 and a 200-day moving average price of $22.96. The company has a quick ratio of 4.28, a current ratio of 4.38 and a debt-to-equity ratio of 6.75.
Institutional investors and hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new stake in shares of Radius Health during the second quarter worth approximately $34,000. Captrust Financial Advisors purchased a new stake in shares of Radius Health during the second quarter worth approximately $38,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Radius Health by 3,130.7% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,423 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 2,348 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Radius Health during the second quarter worth approximately $62,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Radius Health during the first quarter worth approximately $157,000.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Article: Analyst Ratings Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.